Ablexis Announces Validation and Availability of AlivaMab(R) Mouse-NGX
-
'Aura' battles leap from social media to Latin America streets
-
Australia lose three wickets after skittling Bangladesh for 64
-
US, Canada fail to reach trade pact to avert Trump tariffs
-
Bangladesh all out for 64 in 2nd Test after Starc masterclass
-
Sudan farms lie barren as El Nino leaves Nile banks dry
-
Odyssey effect: stars sell Greece to a new wave of US tourists
-
Arctic shipping a daunting prospect in hotly contested region
-
South Korea to send first container ship through Arctic route
-
In US, rare earths extracted from coal mine wastewater
-
Starc takes 5-11 to leave Bangladesh reeling in 2nd Test
-
Nakashima pounds Fritz, Bejlek beats Keys in Cincinnati upsets
-
Injured Rune withdraws from US Open
-
Canadian negotiator says 'more work to do' on US trade deal
-
Nakashima knocks out Fritz to reach Cincinnati semi-finals
-
'Solid' Clark takes solo lead at BMW Championship
-
Ukraine says 'cynical' Russian strike on shopping centre killed 16
-
Arteta hails Arsenal's desire after perfect start to title defence
-
TikTok to pay $400 mn settlement in US children's privacy case
-
Betis down Real Sociedad in La Liga opener
-
MLS fines Messi for striking an opponent
-
Mexican governor resumes job despite US drug charges
-
Gouiri double fires Marseille past Strasbourg in Ligue 1 opener
-
Arsenal rout Coventry to open Premier League season in style
-
Mavericks buy out Thompson, now reportedly bound for Heat
-
Giant-killer Bejlek overhauls Keys to reach Cincinnati semi-finals
-
England v Pakistan first Test: Three talking points
-
Man Utd agree deal for Brighton midfielder Baleba: reports
-
US, Canada push to seal trade deal as deadline nears
-
Werro wins Lausanne 800m, well off world record pace
-
One dead, three wounded after sword attack at Swedish high school
-
China mulls bid to host 2028 UN climate talks: sources
-
Ukraine says 'cynical' Russian strike on shopping centre killed 15
-
Jones becomes third Englishman to join Inter this summer
-
US Supreme Court allows White House ballroom construction for now
-
Mexican governor wanted on US drug charges returns to job
-
Root hails emerging fast bowlers as England thrash Pakistan
-
Bolivia's Paz forced to fire economy minister in mid-crisis
-
Brazil's Lula urges tariffs resolution in call with Trump
-
A-Rod ups T-Wolves stake in $4.5bn ownership change
-
Ukraine says 'cynical' Russian strike on shopping centre killed 14
-
UK court orders Prince Harry, others to pay Daily Mail initial £9.5mn
-
Heatwave-hit Europe logs over 30,000 excess summer deaths: first figures
-
'Grateful' ex-world champion Alaphilippe retires from cycling
-
Give LIV Golf 'one more shot,' says DeChambeau
-
US, Canada work to wrap up trade deal ahead of looming deadline
-
Duplantis hits the high notes for athletics anthem
-
Malaysia's JDT claim unbeaten run world record
-
Malaysia's JDT claims unbeaten run world record
-
At least 2 teens seriously wounded in sword attack at Swedish school
-
Bolivian economy minister fired after Congress vote
Ablexis Announces Validation and Availability of AlivaMab(R) Mouse-NGX
Launching the most advanced transgenic animal platform for human antibody drug discovery
SAN DIEGO, CA / ACCESS Newswire / September 2, 2025 / Ablexis, LLC, a biopharmaceutical company focused on advancing human antibody drug discovery through provision of its AlivaMab Mouse technology, today announced the launch of AlivaMab Mouse-NGX, a next-generation suite of advanced transgenic mice that expand both the number and human variable region diversity of antigen-specific antibodies while retaining their requisite drug-like properties.
"AlivaMab Mouse-NGX strains represent a major evolution of our platforms relative to earlier generations of AlivaMab Mouse, which already outperformed other transgenic models and have yielded at least 18 antibodies entered into clinical trials," said Larry Green, Ph.D., Chief Executive Officer of Ablexis. "Our validation tests confirm that AlivaMab Mouse-NGX strains produce up to six-times the number of antigen-specific antibodies while also exhibiting expansion of combinatorial and junctional diversity versus comparator platforms. AlivaMab Mouse-NGX strains set a new benchmark for success in B-cell- and NGS-based human antibody drug discovery," Dr. Green continued.
The AlivaMab Mouse platform is available for use in-house by Ablexis' licensees or exclusively for service provision through AlivaMab Biologics, including access on a license-free, milestone- and royalty-free basis.
About Ablexis, LLC
Ablexis, LLC creates and offers AlivaMab Mouse, a growing suite of unique, patented next generation transgenic mice, as a foundational platform for successful human antibody drug discovery and development. Dozens of companies, including 13 of the world's top 25 global pharmaceutical companies, public and private biotechnology companies, and other entities have licensed AlivaMab Mouse for their antibody drug discovery. Ablexis' sister company, AlivaMab Biologics provides an integrated antibody therapeutic discovery and engineering platform using the AlivaMab Mouse technologies. For more information, please contact us at [email protected].
###
Media Contact:
Maya Tanaka
[email protected]
SOURCE: Ablexis, LLC
View the original press release on ACCESS Newswire
R.Garcia--AT
